tbuckley/cabot-search huggingface dataset:
Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).
Authors: Manuela A. Bergmann, Barbara F. Eichhorst, Raymonde Busch, Hartmut Doehner, Ursula Vehling-Kaiser, Wolfgang Abenhardt, Michael Hallek
Journal: Blood (2007)
Local IgE Production in Allergic (AR) and Non-Allergic Rhinitis (NAR)
Authors: Ahmed Hamed, Thamiris Palacios, Dilawar Khokhar, Alexander J. Schuyler, John W. Steinke, Thomas A.E. Platts-Mills, Monica G. Lawrence, Larry Borish
Journal: Journal of Allergy and Clinical Immunology (2017)
Whole Exome Analysis Reveals Spectrum of Gene Mutations in Juvenile Myelomonocytic Leukemia
Authors: Hideki Muramatsu, Yusuke Okuno, Hirotoshi Sakaguchi, Kenichi Yoshida, Yuichi Shiraishi, Masashi Sanada, Kenichi Chiba, Hiroko Tanaka, Hideki Makishima, Xinan Wang, Yinyan Xu, Sayoko Doisaki, Asahito Hama, Koji Nakanishi, Yoshiyuki Takahashi, Nao Yoshida, Jaroslaw P. Maciejewski, Satoru Miyano, Seishi Ogawa, Seiji Kojima
Journal: Blood (2012)
BMET-23. TREATMENT OF PATIENTS WITH UP TO 100 BRAIN METASTASES WITH STEREOTACTIC RADIOSURGERY IN THE PERFEXION ERA
Authors: Joy Trybula, Greg Bowden, Ajay Niranjan, John Flickinger, Dade Lunsford, Edward Monaco
Journal: Neuro-Oncology (2016)

Advancements in antineoplastic therapies have extended survival and led to increases in brain metastases. We sought to determine outcomes and prognostic indicators for patients with extensive brain metastases managed with Gamma Knife®stereotactic radiosurgery (SRS). This is a retrospective study of 138 patients treated with SRS for ≥20 brain metastases from lung, breast, and melanoma between 2007 and 2015. Patients harbored a median of 30 metastases (20–100), accounting for 4790 tumors. Fifty-two (38%) patients had ≥ 20 brain metastases treated in an initial single session or planned two-staged treatment within 4 weeks. Eighty-six (62%) patients had ≥20 metastases treated over 2-8 SRS procedures over 2-53 months. Whole brain radiotherapy (WBRT) was performed in 53 patients prior to SRS. The median total tumor volume was 1.55cm3 (0.007–71.7cm3) with a median marginal dose of 16Gy (12–20Gy). The actuarial overall survival from diagnosis of brain metastases was 64% at 1-year and 34% at 2-years. WBRT prior to SRS did not improve survival versus SRS alone (p=0.987). Patients with ≥20 metastasis at first treatment or planned staging experienced a 1-year survival rate of 22% compared to 65% in patients treated over multiple salvage procedures over time (p<0.001). Only 15 of the 85 patients in whom SRS was the upfront treatment strategy underwent salvage WBRT. The median patient survival from diagnosis of brain metastases was 14.5 months for lung cancer, 18.1 months for breast cancer and 10.9 months for melanoma. Survival was associated with tumor histology (p=0.042), total tumor volume (p=0.011), and prior chemotherapy (p=0.009). In these patients with extensive metastatic brain disease SRS alone yielded equivalent survivals when compared to SRS+WBRT. Significantly shorter survival was seen in patients with an upfront plan to treat ≥20 brain metastases. However, an SRS-only strategy in the setting of extensive accumulating metastatic disease is a viable management option.
The Hsp90 Inhibitor, 17-AAG, and Topoisomerase ll Inhibitor, Etoposide, Synergistically Inhibit Leukemias with FLT3 Mutations through Inhibition of DNA Repair Proteins, Chk1 and Rad51.
Authors: Qing Yao, Brenda Weigel, John Kersey
Journal: Blood (2005)
Expression of Circadian Core Clock Gene Per2 Is Markedly Down-Regulated in Diffuse Large B-Cell Lymphoma
Authors: Nils Heinrich Thoennissen, Qi Cao, BaoNgan Doan, Sam Abbassi, Daniel Nowak, C. Müller-Tidow, Jonathan Said, Sigal Gary, H. Phillip Koeffler
Journal: Blood (2008)
Gemcitabine, Dexamethasone and Cisplatin (GDP regimen) As First Salvage Treatment of Patients with Refractory or Relapsed Diffuse large B Cell Non Hodgkin Lymphoma (DLBCL)
Authors: Thoraya Mohamed Abdel Hamid, Mona fawzy Ramadan, Abeer Bahnassy, Fouad Abu- Taleb, Magdy Saber
Journal: Blood (2011)
Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent
Authors: Maria Eugenia Gallo Cantafio, Annamaria Gulla, Nicola Amodio, Emanuela Leone, Eugenio Morelli, Lavinia Biamonte, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone, Maria Teresa Di Martino
Journal: Blood (2015)
Identification of multifunctional cytotoxic T-cell subsets as immune correlates with clinical outcomes in a phase II study of AGS-003, an autologous dendritic cell-based therapy administered to patients with newly diagnosed, metastatic RCC.
Authors: Mark DeBenedette, Igor Jurisica, Alicia H. Gamble, Irina Y. Tcherepanova, W. Lee Williams, Doug Plessinger, Fred Miesowicz, Charles A. Nicolette
Journal: Journal of Clinical Oncology (2012)

80 Background: AGS-003 is an autologous dendritic cell (DC) immunotherapy prepared from matured monocyte-derived DC co-electroporated with the subject’s own amplified tumor RNA and synthetic CD40L RNA. The mechanism of action (MOA) of AGS-003 was evaluated in combination with sunitinib for treatment of advanced renal cell carcinoma (RCC) in AGS-003-006, an open label phase II trial including subjects with newly diagnosed, unfavorable-risk, metastatic clear cell RCC. The goal of the immune monitoring platform is to identify unique cytotoxic T-cell (CTL) signatures that correlate with clinical outcome in subjects receiving AGS-003 in combination with sunitinib. Methods: Multiparametric flow cytometry was used to identify tumor-reactive CTL subsets induced by AGS-003 based on combinatorial expression patterns of surface markers CD28, CD45RA, CD27 and CCR7. Moreover, further partitioning of each CTL subset identified combinatorial expression patterns of Markers of Immune Function (MIFs) defined as cytokines (IFN-γ TNF-α, IL-2), cytolytic markers (Granzyme b, CD107) and proliferation. Correlates of CTL signatures with clinical outcome were analyzed using an adaptation of a binary tree-structured vector quantization (BTSVQ) approach, originally developed to cluster and visualize large microarray data sets. The BTSVQ approach implements a two-way unsupervised clustering that allows a subject’s CTL signature to be mapped based on both surface marker and MIFs expression patterns to identify unique clustering patterns linked to clinical outcome. Results: Data analysis identified a unique CTL signature (CD28 + /CCR7 + /CD45RA - phenotype) displaying a broad MIFs profile as a statistically significant correlate to PFS and OS in patients treated with AGS-003. Conclusions: These results support the intended MOA of AGS-003 in vivo, as the induction of anti-tumor central and effector memory CTL responses. These data warrant further immunological evaluation of AGS-003 in the randomized phase III ADAPT study using AGS-003 in combination with standard treatment in RCC subjects.
Salutary Effect of Pegylated Interferona in PV and ET As Evaluated by Quantitation of Pre-JAK2V617F and JAK2V617F-Bearing Stem Cells and Granulocytes and Correlation with Circulating Regulatory T Cells and HSC Cell Cycle Status
Authors: Sabina Swierczek, Todd W. Kelley, Katherine Y King, Shen Ching-Chieh, Kimberly Hickman, Soo Jin Kim, Mohamed E Salama, Margaret A. Goodell, Josef T. Prchal
Journal: Blood (2012)
Assessment of Clinical Risk Factors for Symptomatic Venous Thromboembolism in Common Cancers: A VERITY Registry Study
Authors: Shankaranarayana Paneesha, Aidan McManus, Roopen Arya, Nicholas Scriven, Tim Nokes, Timothy Farren, Sue Bacon, Anthea Nieland, Denise O’Shaughnessy, Peter Rose
Journal: Blood (2008)
Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase
Authors: Juan Manuel Alonso-Dominguez, Felipe Casado, MariaTeresa Gómez Casares, Ismael Buno, Francisca Ferrer-Marin, Eduardo Anguita, Alicia Arenas, Rafael Del Orbe, Rosa M. Ayala, Pilar Llamas, Pedro Sanchez-Godoy, Carmen Burgaleta, Valentín García-Gutierrez, Juan Luis Steegmann, Joaquin Martinez-Lopez
Journal: Blood (2015)
Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
Authors: Marieta Caganova, Chiara Carrisi, Gabriele Varano, Federica Mainoldi, Federica Zanardi, Pierre-Luc Germain, Laura George, Federica Alberghini, Luca Ferrarini, Asoke K. Talukder, Maurilio Ponzoni, Giuseppe Testa, Takuya Nojima, Claudio Doglioni, Daisuke Kitamura, Kai-M. Toellner, I-hsin Su, Stefano Casola
Journal: Journal of Clinical Investigation (2014)
Hematopoietic Stem Cells Are Intrinsically Protected Against MLL-ENL Mediated Transformation
Authors: Amol Sanjay Ugale, Gudmundur Logi Norddahl, Martin Wahlestedt, Petter Säwén, Pekka Jaako, Cornelis J.H. Pronk, Shamit Soneji, Jorg Cammenga, David Bryder
Journal: Blood (2014)
New Oral Treatments for Asthma through Tissue-Specific Modulation of the GABAA Receptor
Authors: Leggy Arnold, Gloria Forkuo, Amanda Nieman, Olivia B. Yu, Margaret L. Guthrie, Revathi Kodali, Nina Yuan, Rajwana Jahan, Michael S. Stephen, Charles W. Emala, Gene T. Yocum, James M. Cook, Mitchell H. Grayson
Journal: Journal of Allergy and Clinical Immunology (2017)
Analysis of clinical features of ovarian cancer (OC) and breast cancer (BC) among BRCA-mutated (BRCA+) and sporadic (NH) double tumours.
Authors: Maria Ornella Nicoletto, Marco Rocchetto, Grazia Artioli, Alessandra Perin, Cristina Ghiotto, Lucia Borgato, Pasquale Fiduccia, Maurizia Dalla Palma, Haralabos Koussis, Fable Zustovich, Alfredo Ercoli, Pietro Litta, Giovanni B. Nardelli, Vittorina Zagonel
Journal: Journal of Clinical Oncology (2013)

5548 Background: The clinical outcome of double OC and BC is specifically unknown either BRCA+ and in double tumours NH patients. Methods: The present databases made of 106 patients, 67 cases of NH (negative, no-tested or ongoing test for BRCA1/2 mutations) and 39 of BRCA+, were constituted to identify the clinical and pathological features of BC and OC. The primary endpoint was to evaluate biological characteristics of both cancers and clinical outcome of OC in coexistence with BC. Patients were censored at last follow-up or death (any cause) for determination of overall survival (OS). OS were determined using the Kaplan-Meier method and log-rank test to compared the different levels of a variable. Pearson Chi-Square or Fisher’s exact test were used to compare relationship between variables in to groups and Mann-Whitney U test to compare the medians. Results: 32/39 (82 %) BRCA+ and 44/67 (66 %) NH had BC as their first malignancy. As regards the genetic test on NH patients, 28 were BRCA negative, 22 have not been tested and in 10 patients the test is still in progress. All BRCA2 patients had BC as first malignancy, while 20/22 of BRCA1. Bilateral BC was more frequent in BRCA+ than in NH (33 % vs 9 %), resulted in a fivefold higher risk (p = 0.002). III-IV stage OC at diagnosis was 79% in BRCA+ vs 55 % in NH (p = 0.013); indeed BRCA+ patients have a threefold higher risk (however moderate) to develop an advanced stage OC. Death for progression of ovarian cancer involved both groups, and third neoplasm was involved in death cause in 1/1 of BRCA and 5/6 of NH. Two BRCA1 with OC as first neoplasm are alive. Conclusions: III-IV stage OC is more frequent in BRCA+ than in NH, and the main cause of disease progression and death is due to OC. Eventually the most relevant conclusive assessment is the suggestion of a more conserving management for BC and an intensive follow-up for OC in patients with double tumours, irrespective of their pathological or genetic features. Prospective trials are also indicated.
RTHP-17. COMPLIANCE OF TUMOR TREATING ELECTRIC FIELDS THERAPY AND OVERALL SURVIVAL IN GLIOBLASTOMA
Authors: Eric Wong, Johnson Fong
Journal: Neuro-Oncology (2016)

Tumor treating electric fields (TTFields) at 200 kHz is an established therapeutic modality for glioblastoma. These fields exert anti-tumor effects by disrupting tumor cell cytokinesis during metaphase to anaphase transition. Since TTFields therapy has no half-life, uninterrupted application of TTFields at a daily compliance rate of 75% (18 out of 24 hours) is advocated to achieve optimal survival outcome. To confirm the benefit of this compliance rate, we used an unsupervised, binary partitioning algorithm to determine the daily compliance rate and the cumulative compliance that yielded the greatest statistical significance in the median overall survival (OS) of our single-institution cohort (n=28) treated with TTFields from 2012 to 2016. We found that the lowest Wilcoxon P value of 0.0113 corresponded to a daily compliance rate of 76% or 18.2 hours. The difference in the Kaplan-Meier median OS for patients with compliance ≥76% (n=21) and <76% (n=7) was not statistically significant (χ2=1.2, P=0.2650). Kinetic modeling demonstrated objective reduction of tumor size requires at least 6.8 months of TTFields exposure, suggesting a longer time-dependent component for efficacy. Thus, we determined the lowest Wilcoxon P value of 0.0005 for OS that corresponded to a cumulative compliance of 3,658 hours in our cohort. The Kaplan-Meier median OS for patients with cumulative compliance ≥3,658 hours was 17.4 (95%CI 14.2-N/A) months (n=7), which compared favorably to the median OS of 8.1 (95%CI 7.7-N/A) months (n=21) for those with cumulative compliance <3,658 hours (χ2=7.7, P=0.0054). Taken together, cumulative compliance represents the total patient exposure to TTFields, or area under the curve, over a period of 5 to 6 months at a compliance rate near 75%. In our analysis, cumulative compliance was found to be associated with a longer OS than daily compliance rate.
EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence.
Authors: C. Liberatoscioli, J. A. Langendijk, C. Van Herpen, L. Collette, E. M. Ozsahin, R. Karra Gurunath, D. A. Lacombe, A. Gulyban, N. Gosselin, W. Budach
Journal: Journal of Clinical Oncology (2011)

TPS197 Background: The clinical outcome of patients (pts) with resected HNSCC at high risk of recurrence remains poor. Disease free survival (DFS) at 5 years is around 40% after standard adjuvant chemoradiation (CRT). The use of anti-EGFR monoclonal antibodies combined with radiotherapy was shown to be effective in pts with HNSCC, and combination with CRT showed to be safe. Methods: This open-label phase III randomized trial will investigate whether the addition of the anti-EGFR antibody panitumumab to adjuvant CRT significantly prolongs DFS in HNSCC at high risk of recurrence. Pts with high-risk HNSCC, due to the presence of close resection margins (<5 mm) or extracapsular extension, will be randomized to receive 7 weeks of concomitant CRT (three cycles of cisplatin or two cycles of cisplatin and 5-fluorouracil with 66 Gy radiotherapy), +/- weekly panitumumab 2.5 mg/kg. Both IMRT and 3D-RT are allowed in the study, the use of simultaneous integrated boost technique is mandatory. The protocol includes an extensive quality assurance program for radiotherapy. The primary study endpoint is DFS. The study is powered to 80% for showing a 10% increase in 5-year DFS, from 36% to 46% (corresponding to a hazard ratio 0.76) at the 2-sided 5% significance level. Hence, 800 pts must be randomized over 5 years. A restricted cohort of pts participating in the study will also receive a single dose of panitumumab prior to surgery. The aim of this sub-study is to test the predictive potential of a gene expression classifier to identify a subgroup of pts most likely to benefit from the experimental treatment. Two correlative studies are part of the trial, which will investigate the predictive role of biologic assays (lymphocyte apoptosis test and SNPs analysis) and pt/treatment-related parameters on the development of late radiation-induced side effects, and the relationship between treatment toxicity and quality of life. Biomarker evaluation will be performed on tissue and serum samples collected from all consenting pts. The trial opened to recruitment in January 2011.
356P Early stage natural killer/T cell lymphoma with local tumor invasiveness treated with a uniform SMILE protocol: An institutional study from India
Authors: V.G. Gupta, A. Gogia, P. Mehta, L. Kumar, A. Sharma, S. Bakhshi, S. Thulkar, M.C. Sharma, S. Mallick, R.K. Sahoo, P. Malik
Journal: Annals of Oncology (2016)
Relative value of serum cytokines and clinical factors in predicting weight loss in advanced pancreatic cancer (PC).
Authors: D. R. Fogelman, X. S. Wang, M. Hassan, D. Li, M. M. Javle, G. R. Varadhachary, R. T. Shroff, M. J. Overman, R. A. Wolff, J. L. Abbruzzese
Journal: Journal of Clinical Oncology (2011)

208 Background: The identification of PC patients at high risk for cachexia may allow for early intervention to prevent this outcome. Symptoms such as pain, nausea, and anorexia might predict weight loss. Likewise, inflammatory cytokines are also associated with cachexia. We evaluated the ability of each to predict weight loss in patients beginning treatment for PC. Methods: We evaluated 44 newly diagnosed advanced or metastatic PC patients for baseline symptomatology via the M. D. Anderson Symptom Inventory (MDASI). This survey assesses symptom severity, such as nausea, vomiting, fatigue, pain, diarrhea, and constipation, on a 1-10 scale. Baseline serum levels of IL-1a, IL-1b, IGF-1, CXCL-12, CXCL-16, CRP, IL-6, IL-8, VEGF, CEA, and CA 19-9 were assessed. Logistic regression analysis was performed to determine the odds ratio (OR) and confidence interval (CI) for the association of different parameters with 10% weight loss at 60 days from treatment initiation. Student t-test was used to compare the mean values across different strata. Results: A weight loss of &gt;10% was observed in 15 patients (34%). Only the use of mild (but not strong) opioids was associated with weight loss; estimated OR = 6.2 (C.I. 1.2-31.9, p=.03). No association was observed for the MDASI parameters. Baseline levels of cytokines were available for 23 patients. We observed significant differences in the mean values of CXCL-16 (p=.05) and IL-6 (p=.045) in patients with weight loss as compared to those without weight loss. Moreover, serum level of erythropoietin may be negatively associated with weight loss (p=0.06). Conclusions: Alterations in serum cytokine levels may correlate more strongly with cachexia than clinical symptoms and underscore the importance of cytokine analysis in identifying PC patients at high risk for cachexia. [Table: see text]
Thioredoxin reverses age-related hypertension by chronically improving vascular redox and restoring eNOS function
Authors: Rob H. P. Hilgers, Venkatesh Kundumani-Sridharan, Jaganathan Subramani, Leon C. Chen, Luis G. Cuello, Nancy J. Rusch, Kumuda C. Das
Journal: Science Translational Medicine (2017)

Thioredoxin treatment in aged mice reversed hypertension, suggesting a potential therapeutic approach.
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies
Authors: Alain Fischer, Johan Provot, Jean-Philippe Jais, Alexandre Alcais, Nizar Mahlaoui, Daniel Adoue, Nathalie Aladjidi, Zahir Amoura, Philippe Arlet, Corinne Armari-Alla, Brigitte Bader-Meunier, Vincent Barlogis, Sophie Bayart, Beatrice Beaurain, Yves Bertrand, Boris Bienvenu, Stéphane Blanche, Damien Bodet, Bernard Bonnotte, Raphaël Borie, Patrick Boutard, Claire Briandet, Jean-Paul Brion, Carolina Brito, Jacques Brouard, Emilie Catherinot, Olivia Chandesris, Sarah Cohen-Beaussant, Hélène Coignard-Biehler, Laurence Costes, Louis-Jean Couderc, Gérard Couillault, Virginie Courteille, Elodie Curlier, Geneviève de Saint Basile, François Demeocq, Nathalie de Vergnes, Catherine Devoldere, Anne Deville, Jean Donadieu, Eric Dore, Fabienne Dulieu, Isabelle Durieu, Christine Edan, Natacha Entz Werle, Claire Fieschi, Fanny Fouyssac, Pierre Frange, Vincent Gajdos, Lionel Galicier, Virginie Gandemer, Martine Gardembas, Catherine Gaud, Bernard Grosbois, Gaelle Guillerm, Eric Hachulla, Mohamed Hamidou, Sébastien Héritier, Olivier Hermine, Cyrille Hoarau, Bruno Hoen, Arnaud Hot, Sébastien Humbert, Arnaud Jaccard, Serge Jacquot, Jean-Philippe Jais, Rolland Jaussaud, Pierre-Yves Jeandel, Eric Jeziorski, Kamila Kebaili, Anne-Sophie Korganow, Philippe Labrune, Olivier Lambotte, Fanny Lanternier, Claire Larroche, Alain Le Quellec, Emmanuelle Le Moigne, Vincent Le Moing, Yvon Lebranchu, Marc Lecuit, Guillaume Lefevre, Richard Lemal, Philippe Le Moine, Valérie Li Thiao Te, Olivier Lortholary, Patrick Lutz, Aude Magerus-Chatinet, Marion Malphettes, Aude Marie-Cardine, Nicolas Martin Silva, Agathe Masseau, Christian Massot, Françoise Mazingue, Etienne Merlin, Gérard Michel, Frédéric Millot, Odile Minckes, Béatrice Monlibert, Fabrice Monpoux, Despina Moshous, Luc Mouthon, Martine Munzer, Bénédicte Neven, Raphaëlle Nove-Josserand, Eric Oksenhendler, Marie Ouachée-Chardin, Anne Pagnier, Jean-Louis Pasquali, Marlène Pasquet, Isabelle Pellier, Yves Perel, Antoinette Perlat, Capucine Picard, Christophe Piguet, Dominique Plantaz, Pierre Quartier, Frédéric Rieux-Laucat, Pascal Roblot, Pierre-Marie Roger, Pierre-Simon Rohrlich, Bruno Royer, Valéry Salle, Françoise Sarrot-Reynauld, Amélie Servettaz, Jean-Louis Stephan, Nicolas Schleinitz, Felipe Suarez, Laure Swiader, Sophie Taque, Caroline Thomas, Olivier Tournilhac, Caroline Thumerelle, Jean-Pierre Vannier, Jean-François Viallard
Journal: Journal of Allergy and Clinical Immunology (2017)
FREE FATTY ACIDS REPRESS SHP ACTIVATION AND ADIPONECTIN COUNTERACTS BILE ACID INDUCED LIVER INJURY: NEW TARGET OPTIONS FOR NASH TREATMENT?
Authors: Lars Bechmann, Peri Kocabayoglu, Jan-Peter Sowa, Svenja Sydor, Johannes Schmitt, Rebekka Hannivoort, Juergen Treckmann, Christian Rust, Guido Gerken, Andreas Geier, Ali Canbay
Journal: Hepatology (2011)